BioSpace News Archive

Business

Beacon Hill Pharma Arrives in Colorado Springs

This month, Beacon Hill Pharma opened in Colorado Springs, joining Beacon Hill Technologies.

July 8, 2019
·
2 min read
Business

Silicon Therapeutics Expands Board by Naming Roger J. Pomerantz, MD, FACP as Chairman of the Board of Directors and Appointing Mark J. Gilbert, MD as a Board Director

Silicon Therapeutics announced today that it has named Roger J. Pomerantz, MD, FACP, a current member of the Board of Directors, to Chairman and appointed Mark J. Gilbert, MD, to the Board of Directors.

July 8, 2019
·
3 min read
Business

Deciphera Pharmaceuticals, Inc. Announces Appointment of Susan L. Kelley, M.D., to its Board of Directors

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the appointment of Susan L. Kelley, M.D. to its Board of Directors

July 8, 2019
·
7 min read
Business

PerkinElmer to Hold Earnings Call on Monday, July 29, 2019

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that on Monday, July 29, 2019, after market close, the Company will release second quarter 2019 results.

July 8, 2019
·
1 min read
Pharm Country

Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the publication of a study in BMC Biotechnology,

July 8, 2019
·
4 min read
Kither Biotech raises a €5.6m financing round to support the clinical development of a new drug for cystic fibrosis and other pulmonary diseases

Kither Biotech, a spin-off company from the University of Turin focusing on the development of new treatments for pulmonary diseases, announces a Series A financing round of €5.6m

July 8, 2019
·
6 min read
Drug Development

At ESMO GI 2019, TYME Presents Updated Data from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that its multicenter open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging results and a well-tolerated safety profile

July 8, 2019
·
7 min read
Drug Development

New data show efficacy and safety of Pradaxa® in the management of VTE in children

Boehringer Ingelheim announced results from two pediatric studies of Pradaxa®, which were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia.

July 8, 2019
·
10 min read
Genetown

Gamida Cell Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that the underwriters of its recently closed underwritten public offering of 7,000,000 ordinary shares have exercised in full their option to purchase an additional 1,050,000 ordinary shares at the public offering price of $5.00 per share.

July 8, 2019
·
2 min read
Biotech Beach

Providence St. Joseph Health Collaboration With Blue Shield of California and Gemini Health Delivers Immediate Drug Cost Savings for Patients

Patient-specific, drug-cost comparisons for prescriptions now available to hundreds of prescribers at Providence St. Joseph Health

July 8, 2019
·
5 min read